Preemptive Intervention in Airflow Obstruction Status Prevents the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Stem Cell Transplantation: Multicenter, Prospective Phase II Study (Chiba AFO-01)

Background: Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation (allo-HCT) is recognized as pulmonary chronic graft-versus-host disease (GVHD), a progressive, irreversible, and sometimes fatal complication. Periodic pulmonary function testing (PFT) for ea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2023-11, Vol.142 (Supplement 1), p.2204-2204
Hauptverfasser: Tsukamoto, Shokichi, Kimura, Kenji, Nakao, Sanshiro, Takeda, Yusuke, Ohwada, Chikako, Shimizu, Ryo, Nagao, Yuhei, Shono, Katsuhiro, Onoda, Masahiro, Yokota, Akira, Arai, Hironori, Utsu, Yoshikazu, Masuda, Shinichi, Aotsuka, Nobuyuki, Shiko, Yuki, Ozawa, Yoshihito, Ishii, Arata, Matsui, Shinichiro, Takaishi, Koji, Hino, Yutaro, Kayamori, Kensuke, Oshima-Hasegawa, Nagisa, Mitsukawa, Shio, Muto, Tomoya, Mimura, Naoya, Nakaseko, Chiaki, Sakaida, Emiko
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation (allo-HCT) is recognized as pulmonary chronic graft-versus-host disease (GVHD), a progressive, irreversible, and sometimes fatal complication. Periodic pulmonary function testing (PFT) for early diagnosis and timely therapeutic intervention is essential. However, effective monitoring and adequate treatment strategy for BOS have not been established. The airflow obstruction (AFO) criteria (predicted FEV1 second decreased by 5% a year or more, and FEV1-second rate
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2023-178437